New digital scores to evaluate liver cancer treatment response
Novel circulating biomarker digital scores for assessing treatment response in liver cancer
['FUNDING_R21'] · CEDARS-SINAI MEDICAL CENTER · NIH-10651050
This study is looking to create new ways to check how well treatments are working for people with liver cancer, using advanced technology to analyze tiny particles and specific markers in the blood, so patients and their doctors can get clearer information about their progress.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CEDARS-SINAI MEDICAL CENTER (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10651050 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the assessment of treatment response in patients with hepatocellular carcinoma (HCC) after therapies like local ablation and transarterial chemoembolization (TACE). It aims to develop novel circulating biomarker digital scores that utilize advanced technologies to analyze extracellular vesicles and specific mRNA markers related to HCC. By enhancing the accuracy of treatment response evaluations, this research seeks to provide more reliable information for patients and their healthcare providers. The approach combines innovative purification and quantification methods to better understand how well treatments are working.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who have undergone treatment such as local ablation or TACE.
Not a fit: Patients with liver cancer who are not receiving treatment or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of treatment effectiveness for liver cancer, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using digital scoring and biomarker analysis for cancer treatment evaluation, indicating a potential for success in this novel approach.
Where this research is happening
LOS ANGELES, UNITED STATES
- CEDARS-SINAI MEDICAL CENTER — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, JU DONG — CEDARS-SINAI MEDICAL CENTER
- Study coordinator: YANG, JU DONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.